Nothing Special   »   [go: up one dir, main page]

MX2024002779A - Vacunas neumocócicas multivalentes. - Google Patents

Vacunas neumocócicas multivalentes.

Info

Publication number
MX2024002779A
MX2024002779A MX2024002779A MX2024002779A MX2024002779A MX 2024002779 A MX2024002779 A MX 2024002779A MX 2024002779 A MX2024002779 A MX 2024002779A MX 2024002779 A MX2024002779 A MX 2024002779A MX 2024002779 A MX2024002779 A MX 2024002779A
Authority
MX
Mexico
Prior art keywords
multivalent pneumococcal
pneumococcal vaccines
vaccines
multivalent
prevention
Prior art date
Application number
MX2024002779A
Other languages
English (en)
Inventor
Richard Malley
Gang Yao
Fan Zhang
Teresa J Broering
Shite Sebastian
Velupillai Puvanesarajah
Gilles R Besin
Heidi Burke
Yingjie Lu
Janet E Mccombs
Onkar Sharma
Taylor C Stevenson
Original Assignee
Affinivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinivax Inc filed Critical Affinivax Inc
Publication of MX2024002779A publication Critical patent/MX2024002779A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Tecnologías para la prevención y/o tratamiento de infecciones neumocócicas.
MX2024002779A 2021-09-09 2022-09-09 Vacunas neumocócicas multivalentes. MX2024002779A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163242487P 2021-09-09 2021-09-09
US202263353014P 2022-06-16 2022-06-16
PCT/US2022/043156 WO2023039223A1 (en) 2021-09-09 2022-09-09 Multivalent pneumococcal vaccines

Publications (1)

Publication Number Publication Date
MX2024002779A true MX2024002779A (es) 2024-06-11

Family

ID=83593951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002779A MX2024002779A (es) 2021-09-09 2022-09-09 Vacunas neumocócicas multivalentes.

Country Status (9)

Country Link
US (1) US12036276B2 (es)
EP (1) EP4398933A1 (es)
JP (1) JP2024533373A (es)
KR (1) KR20240099160A (es)
AU (1) AU2022342080A1 (es)
CA (1) CA3231684A1 (es)
IL (1) IL311239A (es)
MX (1) MX2024002779A (es)
WO (1) WO2023039223A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906795D0 (en) 1989-03-23 1989-05-10 Carroll Noel Method of preparing vaccines
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
EP0814833B1 (en) 1995-03-22 2003-05-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
TR199801531T2 (xx) 1996-02-09 1998-10-21 Smithkline Beecham Biologicals S.A. Zoster vir�s geni ve �r�n�ne kar�� a��lar.
DK0942983T4 (en) 1996-10-31 2014-12-01 Human Genome Sciences Inc Streptococcus pneumoniae antigens and vaccines
AU740784B2 (en) 1997-04-24 2001-11-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
HUP0002475A3 (en) 1997-07-21 2002-01-28 Baxter Healthcare S A Wallisel Modified immunogenic pneumolysin compositions as vaccines
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6287568B1 (en) 1997-09-09 2001-09-11 The Trustees Of Columbia University In The City Of New York Methods relating to immunogenic dextran-protein conjugates
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
JP2002521058A (ja) 1998-07-27 2002-07-16 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌由来の核酸及びタンパク質
EP2053126A1 (en) 1998-07-27 2009-04-29 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
GB9928678D0 (en) 1999-12-03 2000-02-02 Provalis Uk Ltd Streptococcus pneumoniae antigens
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003044185A2 (en) 2001-11-21 2003-05-30 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism
CN1684707B (zh) 2002-05-14 2012-09-05 诺华疫苗和诊断有限公司 用于细菌性脑膜炎的粘膜结合疫苗
EP1558280B1 (en) 2002-11-07 2014-01-08 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP2311991A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
EP2301571A1 (en) 2003-05-07 2011-03-30 Sanofi Pasteur Inc. Tetravalent meningococcal vaccine with enhanced immunogenicity
GB0318688D0 (en) 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
EP1670509A4 (en) 2003-09-03 2007-10-31 Dendritherapeutics Inc MULTIPLEX VACCINES
US20050112139A1 (en) 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
EP1713917A4 (en) * 2004-02-13 2009-06-17 Sanofi Pasteur Ltd PNEUMOLYSINE DERIVATIVES
US20050226899A1 (en) 2004-04-08 2005-10-13 Mauro Castiglioni Cosmetic mask composition
EP1740604A2 (en) 2004-04-27 2007-01-10 Intercell AG Td antigens
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
JP2008509682A (ja) 2004-08-18 2008-04-03 ガヴァナーズ オブ ザ ユニヴァーシティー オブ アルバータ Ｙｅｂｆを利用するタンパク質の製造方法
FI20041396A0 (fi) 2004-10-29 2004-10-29 Vesa Pekka Hytoenen Uudet mikrobiavidiinit
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US20090202528A1 (en) 2005-02-11 2009-08-13 Thomas Kofoed Surface-Located Streptococcus Pneumoniae Polypeptides
ES2382048T3 (es) 2005-04-08 2012-06-04 Wyeth Llc Composición conjugada de proteína-polisacárido neumococico multivante
US20090148894A1 (en) 2005-08-15 2009-06-11 Broedel Sheldon E Methods for optimizing the secretion of protein in prokaryotes
NZ598367A (en) 2005-09-01 2013-10-25 Novartis Vaccines & Diagnostic Multiple vaccination including serogroup C meningococcus
KR20080090411A (ko) 2005-12-08 2008-10-08 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 면역자극 조성물 및 방법
WO2007081583A2 (en) 2006-01-04 2007-07-19 Children's Medical Center Corporation Anti-pneumococcal preparations and methods of use
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
US20080032340A1 (en) 2006-06-09 2008-02-07 University Of Arizona Peptide motifs for binding avidin or neutravidin
US8148084B2 (en) 2006-06-22 2012-04-03 Dana-Farber Cancer Institute, Inc. Diagnosis of autoimmune disease
EP2041175A4 (en) 2006-06-23 2011-03-16 Augmenta Biolog Llc TARGETED IMMUNOJUGATE
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
WO2008152448A2 (en) 2006-12-21 2008-12-18 Emergent Product Development Uk Limited Streptococcus proteins, and their use in vaccination
CN100579152C (zh) 2007-01-29 2010-01-06 华为技术有限公司 一种播放集团彩铃的方法、系统及装置
EP2108047B1 (en) 2007-01-31 2012-10-24 Pfenex Inc. Bacterial leader sequences for increased expression
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
WO2009023300A2 (en) 2007-04-13 2009-02-19 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
CN101784282B (zh) 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 包含肺炎链球菌荚膜多糖缀合物的疫苗
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009021548A1 (en) 2007-08-10 2009-02-19 Wacker Chemie Ag Expression of full length igg and secretion into the culture medium of prokaryotic cells
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US20090068288A1 (en) 2007-09-07 2009-03-12 Wayne Kruger Topical antiseptic veterinary solution
EP2293815A4 (en) 2008-05-22 2013-04-03 Childrens Medical Center SYNERGISTIC IMMUNOGENIC CONJUGATE FUSION-POLYSACCHARIDE PROTEIN
WO2010078027A1 (en) 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
WO2010071986A1 (en) 2008-12-24 2010-07-01 Sanofi Pasteur Limited Modified steptococcus pneumonia pneumolysin (ply) polypeptides
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
IN2012DN00791A (es) 2009-06-29 2015-06-26 Genocea Biosciences Inc
US9827299B2 (en) 2009-10-09 2017-11-28 Children's Medical Center Corporation Selectively disrupted whole-cell vaccine
EP2335721A1 (en) 2009-12-21 2011-06-22 Institut Pasteur Streptavidin and Biotin-based antigen delivery system
US20110159040A1 (en) 2009-12-30 2011-06-30 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
CN101797381B (zh) 2010-01-29 2012-05-23 中国人民解放军第三军医大学 乙肝病毒抗原与路易斯寡糖的复合物及其制备方法和应用
EP2550289A4 (en) * 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF
EP2563396A2 (en) 2010-04-30 2013-03-06 Augmenta Biologicals LLC Delivery proteins
AU2011316924A1 (en) 2010-10-20 2013-05-02 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US9393294B2 (en) 2011-01-20 2016-07-19 Genocea Biosciences, Inc. Vaccines and compositions against Streptococcus pneumoniae
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
CN108840912B (zh) 2011-05-11 2023-07-04 儿童医疗中心有限公司 修饰的生物素结合蛋白及其融合蛋白和应用
WO2014018904A1 (en) 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
AU2015349787B2 (en) * 2014-11-21 2021-07-29 The Board Of Regents Of The University Of Oklahoma Pneumolysin mutants and methods of use thereof
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US11219680B2 (en) 2017-02-24 2022-01-11 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
US11305001B2 (en) 2017-03-28 2022-04-19 The Children's Medical Center Corporation Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof
MX2020007939A (es) 2018-02-05 2020-09-03 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente nuemococica.
CU24709B1 (es) 2018-03-01 2024-06-11 Biological E Ltd Ácido nucleico que codifica la proteína de superficie neumocócica a1 (pspa1) truncada, constructo de expresión para la expresión de alto nivel de la misma y vacuna conjugada neumocócica
EP3849587A4 (en) * 2018-09-12 2022-06-29 Affinivax, Inc. Multivalent pneumococcal vaccines
EP3849599A4 (en) 2018-09-12 2022-06-29 The Children's Medical Center Corporation Pneumococcal fusion protein vaccines
WO2022178015A1 (en) 2021-02-17 2022-08-25 Vaxcyte, Inc. Purification processes for polysaccharides and polypeptide conjugates thereof
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines

Also Published As

Publication number Publication date
US12036276B2 (en) 2024-07-16
AU2022342080A1 (en) 2024-03-28
WO2023039223A1 (en) 2023-03-16
IL311239A (en) 2024-05-01
CA3231684A1 (en) 2023-03-16
JP2024533373A (ja) 2024-09-12
US20230091255A1 (en) 2023-03-23
EP4398933A1 (en) 2024-07-17
KR20240099160A (ko) 2024-06-28

Similar Documents

Publication Publication Date Title
PH12021550542A1 (en) Multivalent pneumococcal vaccines
MX2024002779A (es) Vacunas neumocócicas multivalentes.
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
CY1122867T1 (el) Συνθεσεις που περιλαμβανουν ενα βακτηριακο στελεχος του blautia hydrogenotrophica για χρηση στην θεραπεια ή προληψη διαρροιας ή δυσκοιλιοτητας
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
NZ726364A (en) Vaccine composition against streptococcus suis infection
PH12019502341A1 (en) Compositions and methods involving probiotic molecules
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2020009736A (es) Composiciones que comprenden cepas bacterianas.
LT3759083T (lt) 2,4-diaminochinazolino dariniai ir jų naudojimas virusinės infekcijos, vėžio ir alergijų gydymui
MX2021009105A (es) Toxinas apxia, apxiia y apxiiia inactivadas.
MX2021002719A (es) Cannabinoides para el tratamiento de infecciones grampositivas incluidas cepas bacterianas resistentes a antibióticos.
PH12019500083A1 (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
CY1124286T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
ZA202211980B (en) Methods and treatment of trauma
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
PH12019550183A1 (en) Treatment of infant colic
ZA202208089B (en) Antibacterial quinolines
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
PH12019502915A1 (en) Immunogenic compositions
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
EP3747451A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR PNEUMOCOCCIC INFECTION
MX2023002339A (es) Vacunas contra infecciones por sars-cov-2.